GigaGen Announces Issuance of US Patent for Functional Analysis Methods in the Discovery and Development of Therapeutic Antibodies
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the United States Patent and Trademark Office has issued U.S. Patent No. 10,329,557, covering methods that enable parallel functional analysis of single cells, a core capability of the company’s Surge™ technology. With its massively parallel single-cell bioassay platform, GigaGen can interrogate complex mixtures of cells in search of promising drug targets and therapeutic candidates.
Read the full press release.